Jacqueline E Mann1,2, Aditi Kulkarni1, Andrew C Birkeland1, Judy Kafelghazal1, Julia Eisenberg1, Brittany M Jewell1, Megan L Ludwig1,3, Matthew E Spector1,4, Hui Jiang4,5, Thomas E Carey1,4,6, J Chad Brenner1,3,4. 1. Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan. 2. Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan. 3. Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor, Michigan. 4. Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan. 5. Department of Biostatistics, University of Michigan Medical School, Ann Arbor, Michigan. 6. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan.
Abstract
BACKGROUND: Laryngeal squamous cell carcinomas (LSCCs) have a high risk of recurrence and poor prognosis. Patient-derived cancer cell lines remain important preclinical models for advancement of new therapeutic strategies, and comprehensive characterization of these models is vital in the precision medicine era. METHODS: We performed exome and transcriptome sequencing as well as copy number analysis of a panel of LSCC-derived cell lines that were established at the University of Michigan and are used in laboratories worldwide. RESULTS: We observed a complex array of alterations consistent with those reported in The Cancer Genome Atlas head and neck squamous cell carcinoma project, including aberrations in PIK3CA, EGFR, CDKN2A, TP53, and NOTCH family and FAT1 genes. A detailed analysis of FAT family genes and associated pathways showed disruptions to these genes in most cell lines. CONCLUSIONS: The molecular profiles we have generated indicate that as a whole, this panel recapitulates the molecular diversity observed in patients and will serve as useful guides in selecting cell lines for preclinical modeling.
BACKGROUND: Laryngeal squamous cell carcinomas (LSCCs) have a high risk of recurrence and poor prognosis. Patient-derived cancer cell lines remain important preclinical models for advancement of new therapeutic strategies, and comprehensive characterization of these models is vital in the precision medicine era. METHODS: We performed exome and transcriptome sequencing as well as copy number analysis of a panel of LSCC-derived cell lines that were established at the University of Michigan and are used in laboratories worldwide. RESULTS: We observed a complex array of alterations consistent with those reported in The Cancer Genome Atlas head and neck squamous cell carcinoma project, including aberrations in PIK3CA, EGFR, CDKN2A, TP53, and NOTCH family and FAT1 genes. A detailed analysis of FAT family genes and associated pathways showed disruptions to these genes in most cell lines. CONCLUSIONS: The molecular profiles we have generated indicate that as a whole, this panel recapitulates the molecular diversity observed in patients and will serve as useful guides in selecting cell lines for preclinical modeling.
Authors: Victoria K Hill; Thomas L Dunwell; Daniel Catchpoole; Dietmar Krex; Anna T Brini; Mike Griffiths; Charles Craddock; Eamonn R Maher; Farida Latif Journal: Epigenetics Date: 2011-03-01 Impact factor: 4.528
Authors: T E Carey; D L Van Dyke; M J Worsham; C R Bradford; V R Babu; D R Schwartz; S Hsu; S R Baker Journal: Cancer Res Date: 1989-11-01 Impact factor: 12.701
Authors: Lluís Nisa; David Barras; Michaela Medová; Daniel M Aebersold; Matúš Medo; Michaela Poliaková; Jonas Koch; Beat Bojaxhiu; Olgun Eliçin; Matthias S Dettmer; Paolo Angelino; Roland Giger; Urs Borner; Marco D Caversaccio; Thomas E Carey; Liza Ho; Thomas A McKee; Mauro Delorenzi; Yitzhak Zimmer Journal: Mol Cancer Res Date: 2018-08-14 Impact factor: 5.852
Authors: Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly Journal: Nat Genet Date: 2011-04-10 Impact factor: 38.330
Authors: Daniel Martin; Maria S Degese; Lynn Vitale-Cross; Ramiro Iglesias-Bartolome; Juan Luis Callejas Valera; Zhiyong Wang; Xiaodong Feng; Huwate Yeerna; Vachan Vadmal; Toshiro Moroishi; Rick F Thorne; Moraima Zaida; Bradford Siegele; Sok C Cheong; Alfredo A Molinolo; Yardena Samuels; Pablo Tamayo; Kun Liang Guan; Scott M Lippman; J Guy Lyons; J Silvio Gutkind Journal: Nat Commun Date: 2018-07-09 Impact factor: 14.919
Authors: Hannah Carter; Christopher Douville; Peter D Stenson; David N Cooper; Rachel Karchin Journal: BMC Genomics Date: 2013-05-28 Impact factor: 3.969
Authors: Christopher Douville; Hannah Carter; Rick Kim; Noushin Niknafs; Mark Diekhans; Peter D Stenson; David N Cooper; Michael Ryan; Rachel Karchin Journal: Bioinformatics Date: 2013-01-16 Impact factor: 6.937
Authors: Uri Ben-David; Benjamin Siranosian; Gavin Ha; Helen Tang; Yaara Oren; Kunihiko Hinohara; Craig A Strathdee; Joshua Dempster; Nicholas J Lyons; Robert Burns; Anwesha Nag; Guillaume Kugener; Beth Cimini; Peter Tsvetkov; Yosef E Maruvka; Ryan O'Rourke; Anthony Garrity; Andrew A Tubelli; Pratiti Bandopadhayay; Aviad Tsherniak; Francisca Vazquez; Bang Wong; Chet Birger; Mahmoud Ghandi; Aaron R Thorner; Joshua A Bittker; Matthew Meyerson; Gad Getz; Rameen Beroukhim; Todd R Golub Journal: Nature Date: 2018-08-08 Impact factor: 49.962
Authors: Molly E Heft Neal; Andrew C Birkeland; Apurva D Bhangale; Jingyi Zhai; Aditi Kulkarni; Susan K Foltin; Brittany M Jewell; Megan L Ludwig; Lisa Pinatti; Hui Jiang; Jonathan B McHugh; Lawence Marentette; Erin L McKean; J Chad Brenner Journal: BMC Cancer Date: 2021-05-29 Impact factor: 4.430
Authors: Paul L Swiecicki; Greg Durm; Emily Bellile; Apurva Bhangale; J Chad Brenner; Francis P Worden Journal: Invest New Drugs Date: 2020-01-24 Impact factor: 3.651
Authors: Gregory J Basura; Joshua D Smith; Susan Ellsperman; Apurva Bhangale; John Chad Brenner Journal: Laryngoscope Investig Otolaryngol Date: 2021-09-13